Development and validation of a stakeholder-driven, self-contained electronic informed consent platform for trio-based genomic research studies
Bethany Y Norton,James Liu,Sara A Lewis,Helen Magee,Tyler N Kruer,Rachael Dinh,Somayeh Bakhtiari,Sandra H. Nordlie,Sheetal Shetty,Jennifer Heim,Yumi Nishiyama,Jorge Arango,Darcy Johnson,Lee Seabrooke,Mitchell Shub,Robert Rosenberg,Michele Shusterman,Stephen Wisniewski,Blair Cooper,Erin Rothwell,Michael C Fahey,M. Wade Shrader,Nancy Lennon,Joyce Oleszek,Wendy Pierce,Hannah Fleming,Mohan Belthur,Jennifer Tinto,Garey Noritz,Laurie Glader,Kelsey Steffan,William Walker,Deborah Grenard,Bhooma Aravamuthan,Kristie Bjornson,Malin Joseph,Paul Gross,Michael C Kruer,the Cerebral Palsy Research Network.
DOI: https://doi.org/10.1101/2024.05.01.24306461
2024-05-03
Abstract:Increasingly long and complex informed consents have yielded studies demonstrating comparatively low participant and with traditional face-to-face approaches. In parallel, interest in electronic consents for clinical and research genomics has steadily increased, yet limited data are available for trio-based genomic discovery studies. We describe the design, development, implementation, and validation of an electronic iConsent application for trio-based genomic research deployed to support genomic studies of cerebral palsy. iConsent development incorporated stakeholder perspectives including researchers, patient advocates, institutional review board members, and genomic data-sharing considerations. The iConsent platform integrated principles derived from prior electronic consenting research and elements of multimedia learning theory. Participant comprehension was assessed in an interactive teachback format. The iConsent application achieved nine of ten proposed desiderata for effective patient-focused electronic consenting for genomic research. Overall, participants demonstrated high and of key human subjects’ considerations. Enrollees reported high levels of with the iConsent, and we found that participant , iConsent , , and were associated with overall . Although opportunities exist to optimize iConsent, we show that such an approach is feasible, can satisfy multiple stakeholder requirements, and can realize high participant and while increasing study reach.
Genetic and Genomic Medicine